State Licensure Requirements
This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation. For more information, visit https://www.pri-med.com/state/state-mandated
Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.
Kentucky: This activity is approved for HB1/Prescribing Controlled Substances and 201 KAR 9:270 Addiction Medicine (MD/PA) by the Kentucky Board of Medical Licensure, ID# 1125-H2.5-PMI2025A
Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.
This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders.
Faculty
Charles E. Argoff, MD, FABPM
Vice Chair, Albany Medical College, Professor of Neurology and Urology
Director, Comprehensive Pain Center, Albany Medical Center, Director, Pain Management Fellowship, Albany, New York
Learn More
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine, Senior Vice-Chair, School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine
Chief, Division of Pain Medicine, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Learn More
Katherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chairperson, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
Learn More
Disclosures
The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:
Charles Argoff, MD, FABPM: Speaker for Averitas Pharma, AbbVie, Lilly, Lundbeck, Impel Pharmaceuticals, Kowa Pharmaceuticals, Nevro Corporation, Scilex Pharmaceuticals, Teva Pharmaceuticals; Researcher for AbbVie; Consultant for Collegium Pharmaceutical, Nevro Corporation, Pain Scripts, Scilex Pharmaceuticals, Shiratronics, Tris Pharma, Vertex Pharmaceuticals, Vertamical, and Xgene Pharma; Investigator for Lundbeck, and Teva Pharmaceuticals; Stock Holder for Pfizer and Trevena.
Katherine Galluzzi, DO, CMD, FACOFP: Advisor for Eli Lilly
Pamela Kushner, MD, FAAFP (Moderator): Speaker for Janssen, Astellas, Bayer, Bausch/Salix
All others in control of content for this activity have disclosed no relevant financial relationships.